PRODUCTS & RD

Drug Development Platform

  ROS (Reactive oxygen species) are byproduct of the normal metabolism. However, excess of ROS can induce autoimmune disease, cardiovascular disease, neurodegenerative disease and cancer.




  That is way the link between ROS and disease inspire our group. We establish an ROS drug screening platform as a turning point to combine high-throughput screening (HTS) technology developed in recent years, the drug can be used to effectively break the link between ROS and diseases to slow down or stop the formation of disease.

  The link between ROS and cancer is studied by Metagone, and for this platform we design: (1) Specific biomarkers: p-DAPK as biomarker, only the cancer cells are injured by the drug (without affecting normal cells). (2) Living cell detection technology: in this platform, Metagone places a tracer protein that immediately reflects the accumulation of ROS. The tracer protein produce fluorescence to accelerate the entire process of screening drugs.




  In addition, Metagone designs a specific real-time tracer for GRCR that can effectively track proteins that are in contact with GPCR and further integrate mass spectrometry. Therefore, using this platform to screen drugs with mass spectrometry technology to find a specific message delivery path is efficient selection of highly specific drugs.






The difference between Metagone platform and other platform:


  The drug discovery services market is expected to reach USD 14.40 Billion by 2022 from USD 8.32 Billion in 2017, at a CAGR of 11.6%. (The report "Drug Discovery Services Market by Process)

Back to page 返回上頁